TrialPath
Anxiety · Atlanta

Anxiety clinical trials in Atlanta

9 recruiting anxiety disorder studies within range of Atlanta. Click any trial for full eligibility criteria and contact info.

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Recruiting

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.

PhasePhase 2
TypeInterventional
AgeAny
WhereGlendale, California, United States + 58 more
SponsorIntra-Cellular Therapies, Inc.
▾Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Recruiting

This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

PhasePhase 2
TypeInterventional
Age18 Years – 65 Years
WhereChino, California, United States + 61 more
SponsorSeaport Therapeutics
▾Tap for details
Apply

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

Recruiting

This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.

PhasePhase 2
TypeInterventional
Age18 Years
WhereBirmingham, Alabama, United States + 50 more
SponsorIntra-Cellular Therapies, Inc.
▾Tap for details
Apply

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Recruiting

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

PhasePhase 2
TypeInterventional
Age18 Years – 65 Years
WhereHuntsville, Alabama, United States + 51 more
SponsorAbbVie
▾Tap for details
Apply

Neurobiological Mechanisms of Aging and Stress on Prospective Navigation

NCT03896529 · Aging, Anxiety, Memory Impairment
Recruiting

Two hallmarks of both healthy aging and age-related disease are 1) memory and navigational deficits, particularly in orienting towards goal locations and planning how to navigate to them, and 2) increased susceptibility to stress and altered regulation of the stress response. However, there are marked individual differences in these age-related changes. The investigators' proposal will help characterize factors that contribute to this variability. Participants will be pseudorandomly assigned to stress-manipulated or control groups. The investigators will give both groups a novel immersive navigation task, validated by the PI in healthy young adults. This paradigm gives participants the opportunity to either (a) flexibly draw on spatial memory in order to plan efficient routes to goal locations, or (b) fall back on inefficient, but cognitively less-demanding, stimulus-response associations (i.e., habits). Using neuroimaging and behavioral measures, the investigators' protocol will test whether experimentally-induced stress leads individuals to bring fewer details about future locations to mind when route planning, and whether such restricted prospective thought ultimately biases participants towards relatively inflexible, habitual actions.

PhaseNA
TypeInterventional
Age65 Years – 80 Years
WhereAtlanta, Georgia, United States
SponsorGeorgia Institute of Technology
▾Tap for details
Apply

Temporal Interference in Psychiatry (TIP): Neuromodulation Using Temporal Interference

NCT07558759 · Anxiety, PTSD
Recruiting

This study aims to understand the neural, behavioral and clinical effects of temporal interference (TI), a type of neuromodulation method, in healthy populations and in individuals with anxiety and stress-related conditions.

PhaseNA
TypeInterventional
Age18 Years – 65 Years
WhereAtlanta, Georgia, United States
SponsorEmory University
▾Tap for details
Apply

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Recruiting

The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

PhasePhase 2
TypeInterventional
Age18 Years – 74 Years
WhereBirmingham, Alabama, United States + 27 more
SponsorReunion Neuroscience Inc
▾Tap for details
Apply

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034 · Adjustment Disorder
Recruiting

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereBirmingham, Alabama, United States + 32 more
SponsorReunion Neuroscience Inc
▾Tap for details
Apply

Morphine or Ketamine for Analgesia

NCT06835504 · Abdominal Pain, Isolated Extremity Fracture, Pain
Recruiting

Pain is common in children presenting to the emergency department but is frequently undertreated, leading to both short- and long-term consequences. Morphine is the standard treatment for children with moderate to severe acute pain, but its use is associated with serious side effects and caregiver and clinician concerns related to opioid administration. The investigators aim to determine if sub-dissociative ketamine is non-inferior to morphine for treating acute pain and a preferable alternative for treating acute pain in children because of its more favorable side effect profile and potential long-term benefits related to pain-related function, analgesic use/misuse, and mental and behavioral health outcomes.

PhasePhase 3
TypeInterventional
Age6 Years – 17 Years
WhereLos Angeles, California, United States + 7 more
SponsorColumbia University
▾Tap for details
Apply